Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALPI | P09923 | 1/20 | 0.33 |
| ▸ | ALPG | P10696 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9123701 | 0.87 | KMT2A (0.41) | ALDH1A1KMT2AADRB2ADRB1TSHR | |
| SCHEMBL17204240 | 0.85 | ALDH1A1 (0.44) | ALDH1A1PTPN1POLBKMT2AADRB2 | |
| SCHEMBL17204118 | 0.80 | ALDH1A1 (0.43) | ALDH1A1PTPN1POLBKMT2ATSHR | |
| SCHEMBL11564217 | 0.79 | PTPN1 (0.41) | ALDH1A1PTPN1POLBKMT2AADRB2 | |
| SCHEMBL9774077 | 0.75 | ALDH1A1 (0.50) | ALDH1A1PTPN1POLBKMT2A | |
| SCHEMBL974357 | 0.74 | ALDH1A1 (0.44) | ALDH1A1PTPN1POLBKMT2A | |
| SCHEMBL972974 | 0.74 | ALDH1A1 (0.44) | ALDH1A1PTPN1POLBKMT2A | |
| SCHEMBL9121666 | 0.73 | ADRB2 (0.56) | KMT2AADRB2ADRB1SMN1; SMN2 | |
| SCHEMBL974832 | 0.73 | TP53 (0.46) | ALDH1A1PTPN1POLB | |
| SCHEMBL17204428 | 0.72 | ELANE (0.54) | ALDH1A1PTPN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426433-B2 | Anticoagulant compounds, pharmaceutical compositions on their basis to treat thrombotic conditions, and plasma-substituting solution to correct hypercoagulation defects of hemodilution | Obschestvo S Ogranichennoi Otvetsttvennoctiyu “Bionika” (RU) | 2013-04-23 | — | — | US | disclosed |
| US-20110003826-A1 | ANTICOAGULANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS TO TREAT THROMBOTIC CONDITIONS, AND PLASMA-SUBSTITUTING SOLUTION TO CORRECT HYPERCOAGULATION DEFECTS OF HEMODILUTION | Obschestvo S Organichennoi Otvetsttvennoctiyu "Bio (RU) | 2011-01-06 | — | — | US | disclosed |
| US-20100324058-A1 | THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | OBSCHESTVO S ORGANICHENNOI OTVETSTTVENNOCTIYOU "BIONIKA" (RU) | 2010-12-23 | — | — | US | disclosed |
| CN-101861304-A | Thrombin functional compounds and pharmaceutical compositions based thereon | BIONIKA | 2010-10-13 | — | — | CN | disclosed |
| EP-2178838-A2 | NEW THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | Obschestvo S Ogranichennoi Otvetsttvennoctiyu "Bionika" (RU) | 2010-04-28 | — | — | EP | disclosed |
| EP-2178839-A2 | NEW ANTICOAGULANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS TO TREAT THROMBOTIC CONDITIONS, AND PLASMA-SUBSTITUTING SOLUTION TO CORRECT HYPERCOAGULATION DEFECTS OF HEMODILUTION | Obschestvo S Ogranichennoi Otvetsttvennoctiyu "Bionika" (RU) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009002228-A2 | NEW THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | OBSCHESTVO S OGRANICHENNOI OTVETSTTVENNOCTIYU 'BIONIKA' (RU) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002229-A2 | NEW ANTICOAGULANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS TO TREAT THROMBOTIC CONDITIONS, AND PLASMA-SUBSTITUTING SOLUTION TO CORRECT HYPERCOAGULATION DEFECTS OF HEMODILUTION | OBSCHESTVO S OGRANICHENNOI OTVETSTTVENNOCTIYU 'BIONIKA' (RU) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324058-A1 | THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | F2, PLAT, SERPINC1 | ALDH1A1 4317/4885PTPN1 2327/4885POLB 4347/4885 |
| US-20110003826-A1 | ANTICOAGULANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS TO TREAT THROMBOTIC CONDITIONS, AND PLASMA-SUBSTITUTING SOLUTION TO CORRECT HYPERCOAGULATION DEFECTS OF HEMODILUTION | F2, PROC, PLG | ALDH1A1 3871/4885PTPN1 3166/4885POLB 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.